Efficacy and Safety of Prophylaxis with BAY 81-8973 in Chinese Patients with Severe Haemophilia A Enrolled in the LEOPOLD II Trial

Overview

Journal Haemophilia

Specialty Hematology

Date 2019 Apr 18

PMID 30993836

Citations 4

Authors

Renchi Yang

Jing Sun

Yongqiang Zhao

Xuefeng Wang

Depei Wu

Despina Tseneklidou-Stoeter

Junde Wu

Nikki Church

Affiliations

Soon will be listed here.

Abstract

Introduction: BAY 81-8973 (Kovaltry ) is a full-length, unmodified recombinant human factor VIII approved in China for prophylaxis and on-demand treatment in patients with haemophilia A. Limited access to FVIII prophylaxis in China has historically led to this population being undertreated. This subanalysis of LEOPOLD II investigated whether the efficacy and safety of BAY 81-8973 varied between Chinese and non-Chinese patients.

Aim: To evaluate BAY 81-8973 efficacy and safety in Chinese patients.

Methods: LEOPOLD II enrolled males aged 12-65 years with severe haemophilia A who were receiving on-demand treatment. Patients were randomly assigned to receive BAY 81-8973 as low-dose prophylaxis (20-30 IU/kg twice-weekly), high-dose prophylaxis (30-40 IU/kg 3 times weekly) or on-demand for 1 year.

Results: Data were available from 23 Chinese and 57 non-Chinese patients; Chinese patients had a higher prestudy bleeding rate and were more likely to have target joints than non-Chinese patients. 74% of patients were assigned to prophylaxis. Annualized bleeding rates (ABRs) in Chinese and non-Chinese patients receiving prophylaxis were significantly lower compared to patients treated on-demand. Median ABRs for all bleeds in the last 6 months of the study were 2.0 and 1.0 for Chinese and non-Chinese patients, respectively, in the combined prophylaxis groups, and 61.3 and 58.5 in the on-demand group. A treatment-related adverse event occurred in 1 Chinese patient; no patients developed FVIII inhibitors.

Conclusion: BAY 81-8973 prophylaxis was efficacious and well tolerated in Chinese patients with severe haemophilia A, with ABRs comparable to those in non-Chinese patients receiving prophylaxis.

Citing Articles

A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients.

Jamal M, Sathar J, Jamari J, Mohd Saffian S Malays J Med Sci. 2023; 30(1):129-136.

PMID: 36875203 PMC: 9984116. DOI: 10.21315/mjms2023.30.1.11.

Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

Olasupo O, Lowe M, Krishan A, Collins P, Iorio A, Matino D Cochrane Database Syst Rev. 2021; 8:CD014201.

PMID: 34407214 PMC: 8407508. DOI: 10.1002/14651858.CD014201.

Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.

Sun J, Zhou X, Hu N Orphanet J Rare Dis. 2021; 16(1):287.

PMID: 34174912 PMC: 8236177. DOI: 10.1186/s13023-021-01919-w.

Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.

Yang R, Sun J, Zhao Y, Wang X, Wu D, Tseneklidou-Stoeter D Haemophilia. 2019; 25(3):e153-e158.

PMID: 30993836 PMC: 6850381. DOI: 10.1111/hae.13751.

References

Yang R, Sun J, Zhao Y, Wang X, Wu D, Tseneklidou-Stoeter D . Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia. 2019; 25(3):e153-e158. PMC: 6850381. DOI: 10.1111/hae.13751. View

Zhao Y, Xiao J, Yang R, Wu R, Hu Y, Beckmann H . Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A. Pediatr Hematol Oncol. 2017; 34(3):138-148. DOI: 10.1080/08880018.2017.1313921. View

Tang L, Wu R, Sun J, Feng X, Zhang X, Luke K . Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia. 2012; 19(1):27-34. DOI: 10.1111/j.1365-2516.2012.02926.x. View

Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2014; 13(3):360-9. PMC: 4671268. DOI: 10.1111/jth.12828. View

Yao W, Xiao J, Cheng X, Feng G, Li C, Zhang X . The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study. Clin Appl Thromb Hemost. 2016; 23(7):851-858. DOI: 10.1177/1076029616679507. View

Garger S, Severs J, Regan L, Hesslein A, Ignowski J, Wu P . BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics. Haemophilia. 2016; 23(2):e67-e78. DOI: 10.1111/hae.13148. View

Dunkley S, Lam J, John M, Wong R, Tran H, Yang R . Principles of haemophilia care: The Asia-Pacific perspective. Haemophilia. 2018; 24(3):366-375. DOI: 10.1111/hae.13425. View

Srivastava A, Brewer A, Mauser-Bunschoten E, Key N, Kitchen S, Llinas A . Guidelines for the management of hemophilia. Haemophilia. 2012; 19(1):e1-47. DOI: 10.1111/j.1365-2516.2012.02909.x. View

Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R . Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-44. DOI: 10.1056/NEJMoa067659. View

10.

Kepa S, Horvath B, Reitter-Pfoertner S, Schemper M, Quehenberger P, Grundbichler M . Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. Haemophilia. 2015; 21(3):343-350. DOI: 10.1111/hae.12592. View

11.

Ozelo M, Matta M, Yang R . Meeting the challenges of haemophilia care and patient support in China and Brazil. Haemophilia. 2012; 18 Suppl 5:33-8. DOI: 10.1111/j.1365-2516.2012.02890.x. View

12.

Saxena K, Lalezari S, Oldenburg J, Tseneklidou-Stoeter D, Beckmann H, Yoon M . Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016; 22(5):706-12. DOI: 10.1111/hae.12952. View

13.

Wu R, Luke K . The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China. Expert Rev Hematol. 2017; 10(11):995-1004. DOI: 10.1080/17474086.2017.1386096. View

14.

Wang T, Zhang L, Li H, Zhao H, Yang R . Assessing health-related quality-of-life in individuals with haemophilia in China. Haemophilia. 2004; 10(4):370-5. DOI: 10.1111/j.1365-2516.2004.00917.x. View

15.

Wu R, Wu X, Zhang N, Zhao L, Zhang J, Luke K . Joint disease status of severe and moderate haemophilia patients at the Beijing Children's Hospital: early onset and rapid increasing severity of arthropathy in 90% of patients by 6 years of age. Haemophilia. 2014; 20(3):e227-30. DOI: 10.1111/hae.12394. View

16.

Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R . Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia. 2007; 13(4):351-6. DOI: 10.1111/j.1365-2516.2007.01472.x. View

17.

Poon M, Luke K . Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia. 2008; 14(5):879-88. DOI: 10.1111/j.1365-2516.2008.01821.x. View

18.

Ljung R, Kenet G, Mancuso M, Kaleva V, Rusen L, Tseneklidou-Stoeter D . BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia. 2015; 22(3):354-60. DOI: 10.1111/hae.12866. View